“Steel Therapeutics, Inc., an early stage pharmaceutical company focused on increasing access to compounded drug therapies, announced today that it has closed on $1.5M in financing in an over-subscribed seed round.”

“Founded in 2020 by Matt Stahl and Robbie Schwenker, the company hopes to take compounding drugs through the FDA approval process, making them more widely and easily available.”

“Steel Therapeutics is a pharmaceutical company founded by Matt Stahl, Robbie Schwenker, and Allen Phillips in 2020. The team at Steel is working to bring innovations in compounding drugs to the masses.”

“Stahl said he didn’t mind not getting to work with coaches and fellow participants in person. In fact, he believes the opportunity to work virtually actually helped Steel Therapeutics as he expects to be doing a lot of virtual pitches to investors moving forward.”

“‘The FDA did not object to our proposed development path and otherwise offered feedback that is aligned our vision and desired timeline,’ said Steel CEO and Founder Matt Stahl. ‘The correspondence gives us confidence in our approach to bringing the Fizurex wipe to patients at scale.’”